Bannerbild German Brest Group

GBG Research at ESMO Breast Cancer 2019

02.05.2019

Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

#1080: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database

  • Session: Type: Proffered Paper session; Title: Best abstracts session; 3.05.2019, 16:45 - 17:00 (oral presentation)
  • First author: J. Huober J; Universitätsfrauenklinik Ulm, Germany

#15P: Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

  • Session: Type: Poster display session; Title: Poster lunch; 3.05.2019, 12:15 - 13:00 (poster)
  • First author: P. Jank; Charité Universitaetsmedizin Berlin, Germany

#25P: Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment

  • Session: Type: Poster display session; Title: Poster lunch; 03.05.2019; 12:15 - 13:00 (poster)
  • First author: C. Denkert; Institut für Pathologie Philipps-Universität Marburg, Germany

#122TiP: GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

  • Session: Early breast cancer: Neoadjuvant therapy; 3.05.2019; 12:15 – 13:00 (poster, trial in progress)
  • First author: S. Loibl; GBG, Neu-Isenburg, Germany

https://www.esmo.org/Conferences/ESMO-Breast-Cancer-2019/Programme

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd